Singapore’s health tech startup Biofourmis announced a collaboration with global healthcare company Novartis to form a commercial project for managing patients with heart failure.
The program aims to improve clinical outcomes by using Biofourmis’ flagship product, BiovitalsHF, which captures data from wearable sensors.
Before expanding globally, the program is set to start in five countries in Southeast Asia, including Singapore.
Founded in 2015 in Singapore, Biofourmis closed a US$35 million series B funding round in May and moved its headquarters from Singapore to Boston.
“The ultimate goal of this alliance is to work with Novartis to drive better patient-centric outcomes and arm providers across the globe with the right actionable information early enough to better manage their patients with heart failure,” said Biofourmis founder and CEO Kuldeep Singh Rajput.